MAPT and Alzheimer disease: This comprehensive approach enables researchers to identify critical transition points—for instance, whether pTau231 peak concentrations drive subsequent tau pathological deposition—and threshold effects where specific protein concentrations might predict Alzheimer’s disease or CTE risk 5–10 years post-injury (8).